View this email as a webpage

Rutgers Cancer Institute of New Jersey



Clinical Trials Connection

A Cancer Resource for Healthcare Professionals December 2014

Resources for Physicians

Send to a Colleague

Join Our Mailing List

Howard L. Kaufman, MD, FACS, is the associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey. As a member of the Cancer Institute's Melanoma and Soft Tissue Oncology Program, Dr. Kaufman specializes in the evaluation and treatment of melanoma, other forms of skin cancer and sarcomas He currently leads a number of immunotherapy clinical trials at the Cancer Institute.

Contact Dr. Kaufman:
howard.kaufman@rutgers.edu
732-235-7701

Clinical Trial Spotlight

Immunotherapy Clinical Trials

View printable version

A Phase Ib/II Study of Talimogene/ Laherparepvec/ Ipilimumab vs. Ipilimumab for Stage IIIb-IV Melanoma

The study aims to:

- Phase Ib: determine the safety and tolerability of talimogene laherparepvec in combination with ipilimumab as assessed by incidence of dose-limiting toxicities (DLT) in subjects with previously untreated, unresectable, stages IIIb to IV melanoma.
- Phase II: estimate the efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone as assessed by overall survival (OS) in subjects with previously untreated, unresectable, stages IIIb to IV melanoma.

Learn more about this trial

Phase II Single-arm Trial to Evaluate the Biodistirubtion and Shedding of Talimogene Laherparepvec

The study aims to:

- Estimate the proportion of subjects with detectable talimogene laherparepvec DNA in the blood and urine anytime after administration of talimogene laherparepvec within the first 3 cycles.
- Estimate the incidence of clearance of talimogene laherparepvec DNA from blood and urine overall

Phase III POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma with High Risk of Recurrence

The purpose of this study is to evaluate the safety and biological activity of POL-103A in patients with stage IIB, IIC, or III melanoma and to select the dose for Part B.

Learn more

Other Available Trials

Breast

Gastrointestinal/ Hepatobiliary

Gynecologic

Hematologic

Melanoma

Phase I

Prostate

Thoracic

NCI CCC

A Comprehensive Cancer Center Designated by the National Cancer Institute

and by baseline herpes simplex virus type 1 (HSV-1) serostatus(seronegative versus seropositive) during each of the first three cycles.

Learn more about this trial

A Phase I Trial of MSB0010718C in Melanoma and NSCLC

The study aims to:

- Assess the safety and tolerability of MSB0010718C and to determine the maximum tolerated dose (MTD) of MSB0010718C in subjects with metastatic or locally advanced solid tumors.
- Characterize the pharmacokinetic (PK) profile of MSB0010718C and to correlate exposure with target occupancy.
- Evaluate the immunogenicity of MSB0010718C and to correlate it to exposure and biological activity.

Learn more about this trial

A Safety Study for MSB0010445 in Combination with Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment with Ipilimumab

The study aims to:

- Determine the maximum tolerated dose (MTD) of MSB0010445 in combination with Stereotactic Body Radiation Therapy (SBRT) in subjects with advanced melanoma.
- Establish that MSB0010445 in combination with SBRT is clinically active through the observation of best overall response assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
- Characterize the safety of MSB0010445 in combination with SBRT.
- Characterize the immunogenicity of MSB0010445.
- Characterize the pharmacokinetics (PK) of MSB0010445.

Learn more about this trial

EMR 100070-003: A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects with Merkel Cell Carcinoma

The study aims to:

- Assess the clinical activity of MSB0010718C in subjects with metastatic Merkel cell carcinoma (MCC) as determined by the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by an Independent Endpoint Review Committee (IERC).
- Assess the duration of response according to RECIST 1.1.
- Assess the progression-free survival time (PFS) according to RECIST 1.1.
- Assess the safety profile of MSB0010718C in subjects with MCC.
- Assess the overall survival (OS) time.

Learn more about this trial

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state. The Cancer Institute currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies nationwide is fewer than five percent of all adult cancer patients.
Learn more

Cancer Institute of New Jersey | Rutgers, The State University of New Jersey | 195 Little Albany St. | New Brunswick | NJ | 08903